From a shortlist of twenty early-stage startups in the MedTech Actuator Origins 2021 program, outerspace mentoree Vysum emerged as the winner of the Johnson & Johnson Award at the MedTech Actuator Showcase event.
The Vysum team is developing a handheld device to make eye drop administration more convenient for glaucoma patients to improve treatment compliance and prevent blindness.
As participants in the MedTech Actuator Origins program they recently took to the stage in Melbourne to pitch to industry leaders including the largest names in medical technology and investors.
Senior Director of New Ventures, Australia and New Zealand for Johnson & Johnson Innovation, Kathy Connell presented the J&J MedTech Actuator Origin Award to Vysum team members Lorace (Tianshu) Zhang, David Lin and Isaac Ho.
Vysum won the prestigious award after a highly competitive process, intensive immersion sprints and industry-led mentoring by the outerspace team.
“outerspace are very switched on, friendly, professional and generous with the support and help they provided to Vysum. They are resourceful and efficient and supported us to make the most of the funds we had available,” says Lorace Zhang.
As the J&J MedTech Actuator Origin Award 2021 winner, Vysum receives $15 000 in prize money, fast-tracked application to the MedTech Actuator, and in-kind support.
“It was a delight mentoring Vysum. They listened, understood and very importantly actioned the advice we provided,” says Paul Carboon, Business Development specialist at outerspace.
Our experienced medical product developers worked with Vysum to establish their key value propositions, how and when to communicate key points when pitching, and the best style and approach to use – and advised them on core product development technologies.
“We are very proud to have supported Vysum in winning this prestigious award and look forward to working with them moving forward. Vysum are one to watch,” says Carboon.
The team at Vysum first collaborated during a year-long BioDesign Innovation subject at The University of Melbourne. Vysum includes entrepreneurs from the Melbourne Business School and the School of Engineering.
After surveying over 400 glaucoma patients and interviewing over 30 clinicians, Vysum identified problems with accuracy and compliance of treatment administration.
Their eye drop device, Ocumate, makes treatment more accurate, convenient and enjoyable for glaucoma patients and clinicians, ultimately connecting patients and clinicians for improved care.